Concomitant and Sequential Radiohormonotherapy in Adjuvant Breast Cancer
Status:
Completed
Trial end date:
2007-02-01
Target enrollment:
Participant gender:
Summary
This trial will compare grade 2 or greater late skin toxicities of concomitant
letrozole-radiotherapy and radiotherapy followed by letrozole as adjuvant therapy for
postmenopausal women with receptor (estrogen receptor [ER] and/or progesterone receptor
[PgR]) positive tumors. Each drug will be prescribed for 5 years.